Radioligand Therapy in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 44
Special Issue Editor
Interests: nuclear medicine; radiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue of Cancers on “Radioligand Therapy in Cancer”. Radioligand therapy in cancer is considered one of the most promising approaches to cancer treatment, through which precise administration of radioligand limits damage to healthy organs and allows for the administration of higher therapeutic doses. In recent years, several radioligands have successfully joined the arsenal for routine treatment of prostate cancer and neuroendocrine tumors. However, several clinical dilemmas still complicate the use of radioligands, including patient selection, dosimetry schemes, and the detailed role of imaging. This Special Issue covers all important topics in radioligand therapy, including dosimetry, patient selection, toxicity assessment and reduction, efficacy assessment and improvement, new therapeutic radioligands, the role of imaging in radioligand therapy, and artificial intelligence and machine learning in radioligand therapy.
Dr. Ahmad Shariftabrizi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PSMA and SSTR targeting radiopharmaceuticals
- old and novel targets for radioligand therapy
- dosimetry
- toxicity evaluation and reduction
- machine learning and artificial intelligence in radionuclide therapy
- novel radiopharmaceutical
- regulatory aspects of radioligand therapy
- patient selection optimization
- radioligand therapy for neuroblastoma and other pediatric malignancies
